Corporate Presentation
Our R&D pipeline addresses unmet medical needs
across several therapeutic areas
Inflam-
T1DM
mation
Rare
diseases
Obesity
Product candidatea
Partnered
ZEAL&
ZEALAND PHARMA
Pre-clinical
Phase 1
Phase 2
Phase 3
Registration
Dapiglutide (GLP-1R/GLP-2R dual agonist)
Petrelintide (amylin analog)
ZP6590 (GIP receptor agonist)
Survodutide (GCGR/GLP-1R dual agonist) b
Dasiglucagon: SC continuous infusion
Glepaglutide (GLP-2 analog)
ZP9830 (Kv1.3 ion channel blocker)
ZP10068 (complement C3 inhibitor)c
Obesity
Obesity
Obesity
Boehringer
Ingelheim
Obesity and MASH
ALEXION
Congenital hyperinsulinism
Short bowel syndrome
Undisclosed
Undisclosed
AstraZeneca Rare Disease
Dasiglucagon: bi-hormonal artificial pancreas systems
Dasiglucagon: mini-dose pen
T1DM management
T1DM exercise-induced hypoglycemia
aInvestigational compounds whose safety and efficacy have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.
bSurvodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries): EUR 315 million
outstanding potential development, regulatory and commercial milestones + high single to low double digit % royalties on global sales;
Licensed to Alexion: USD $610 million potential development, regulatory and commercial milestones and high single to low double digits percentage royalties on net sales.
GCGR-glucagon receptor; GIP=gastric inhibitory polypeptide; GLP-1R-glucagon-like peptide-1 receptor; GLP-2-glucagon-like peptide-2; GLP-2R-glucagon-like peptide-2 receptor; MASH-metabolic dysfunction-associated steatohepatitis
(formerly NASH, or nonalcoholic steatohepatitis); SC=subcutaneous; T1DM-type 1 diabetes mellitus.
60View entire presentation